aTYR PHARMA INC (ATYR)

0.85 0 (0.09%)

As of 2026-04-02 17:32:03 EST

aTyr Pharma is a public biotherapeutics company (Nasdaq: LIFE) that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease (ILD), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.

Traded asNasdaq: ATYR
ISINUS0021202025
CIK0001339970
LEI529900ENQUXMC5EBKO36
EIN203435077
SectorBiotechnology
IndustryBiological Products, (No Diagnostic Substances)
CEOSanjay S Shukla
Employees55
Fiscal Year End1231
Address10240 SORRENTO VALLEY ROAD, SAN DIEGO, CA, 92121
Phone8587318389
Websitehttp://atyrpharma.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
ATYRaTYR PHARMA INC2026-04-02 17:32:030.8500.09
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
ATYR0001339970aTYR PHARMA INCUS0021202025529900ENQUXMC5EBKO36203435077Nasdaq2836Biological Products, (No Diagnostic Substances)1231DE10240 SORRENTO VALLEY ROADSAN DIEGOCA92121UNITED STATESUS858731838910240 SORRENTO VALLEY ROAD, SAN DIEGO, CA, 9212110240 SORRENTO VALLEY ROAD, SAN DIEGO, CA, 92121—Biotechnology2005Sanjay S Shukla55http://atyrpharma.com463,822,83498,031,10498,051,212aTyr Pharma is a public biotherapeutics company (Nasdaq: LIFE) that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease (ILD), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.2026-04-02 19:30:47
This is a preview of the latest data. Subscribe to access the full data.
ATYR Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
ATYR Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
2025463,822,834347,580,105299.012398,051,2129,192,60010.3452
2024116,242,729-4,531,687-3.752288,858,61221,108,58831.1566
2023120,774,41643,580,30956.455567,750,02414,587,97227.4406
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Jill M. BroadfootChief Financial Officer2025471,790——113,22911,2141,309,913
Sanjay S. ShuklaCEO, President2025638,977——210,86211,2143,456,253
Nancy E. DenyesGeneral Counsel2025451,570——108,37711,2141,284,841
Sanjay S. ShuklaCEO, President2024580,887——246,87710,9981,480,522
Jill M. BroadfootChief Financial Officer2024428,899——145,82610,998746,163
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
202558
202459
202359
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue190,000235,000353,000
Cost Of Revenue———
Gross Profit———
Research And Development Expenses60,219,00054,372,00042,293,000
General And Administrative Expenses17,598,00013,777,00012,979,000
Operating Expenses77,817,00068,149,00055,272,000
Operating Income-77,627,000-67,914,000-54,919,000
Net Income-74,118,000-64,023,000-50,389,000
Earnings Per Share Basic-0.8-0.86-0.94
Earnings Per Share Diluted-0.8-0.86-0.94
Weighted Average Shares Outstanding Basic92,985,35974,261,26553,606,488
Weighted Average Shares Outstanding Diluted92,985,35974,261,26553,606,488
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents10,743,00011,055,00022,544,000
Marketable Securities Current67,944,00061,070,00075,622,000
Accounts Receivable———
Inventories———
Non Trade Receivables———
Other Assets Current677,0008,093,0002,390,000
Total Assets Current80,237,00081,954,000102,992,000
Marketable Securities Non Current———
Property Plant And Equipment4,263,0004,850,0005,531,000
Other Assets Non Current148,00066,000131,000
Total Assets Non Current12,766,00014,876,00017,661,000
Total Assets93,003,00096,830,000120,653,000
Accounts Payable3,891,0004,323,0003,529,000
Deferred Revenue———
Short Term Debt———
Other Liabilities Current9,791,0009,392,00011,559,000
Total Liabilities Current15,148,00014,967,00016,416,000
Long Term Debt———
Other Liabilities Non Current———
Total Liabilities Non Current———
Total Liabilities———
Common Stock98,00084,00063,000
Retained Earnings-606,164,000-532,046,000-468,023,000
Accumulated Other Comprehensive Income-8,000-40,000-74,000
Total Shareholders Equity67,480,00070,019,00090,658,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization664,000708,000592,000
Share Based Compensation Expense———
Other Non Cash Income Expense12,0003,0006,000
Change In Accounts Receivable———
Change In Inventories———
Change In Non Trade Receivables-863,000-402,000-9,054,000
Change In Other Assets———
Change In Accounts Payable-33,000-1,339,0003,262,000
Change In Other Liabilities———
Cash From Operating Activities-61,986,000-69,119,000-33,221,000
Purchases Of Marketable Securities93,445,00069,103,000106,977,000
Sales Of Marketable Securities88,457,00086,394,00091,050,000
Acquisition Of Property Plant And Equipment77,00065,0004,215,000
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities-5,053,00017,233,000-20,127,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock66,400,00040,300,00018,400,000
Repurchase Of Common Stock———
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities19,00000
Cash From Financing Activities66,011,00039,864,00066,230,000
Change In Cash-1,028,000-12,022,00012,882,000
Cash At End Of Period10,743,00011,055,00022,544,000
Income Taxes Paid———
Interest Paid94,000137,000172,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share-0.8-0.86-0.94
Price To Earnings Ratio-0.9789-4.2093-1.5
Earnings Growth Rate-6.9767-8.5106-41.25
Price Earnings To Growth Ratio0.14030.49460.0364
Book Value Per Share0.83731.10241.9445
Price To Book Ratio0.93533.28380.7251
Ebitda-73,454,000-63,315,000-49,797,000
Enterprise Value———
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio———
Capital Expenditures77,00027,0003,064,000
Free Cash Flow-62,063,000-69,146,000-36,285,000
Return On Equity-1.0984-0.9144-0.5558
One Year Beta0.99360.72670.7842
Three Year Beta0.87160.82220.8375
Five Year Beta0.86210.80220.8372
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
DENYES NANCYGeneral Counsel2026-02-041,118D33,124
Broadfoot Jill MarieChief Financial Officer2026-02-041,558D37,296
Shukla SanjayDirector, President and CEO2026-02-043,745D153,553
DENYES NANCYGeneral Counsel2026-02-032,687A34,242
DENYES NANCYGeneral Counsel2026-02-032,687D0
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
Ares Financial Consulting, LLC2026-03-311,7022,0000.851
GOLDMAN SACHS GROUP INC2025-12-31270,629345,5870.7831
HSBC HOLDINGS PLC2025-12-3112,10016,1360.7499
Rockefeller Capital Management L.P.2025-12-3122,01928,1180.7831
Caitong International Asset Management Co., Ltd2025-12-3152670.7761
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
Global X Funds2026-01-31Global X Russell 2000 ETFRSSL40,66035,894.650.0026
ProFunds2026-01-31SMALL-CAP PROFUND SERVICE CLASSSLPSX10088.280.0012
ProFunds2026-01-31SMALL-CAP PROFUND INVESTOR CLASSSLPIX10088.280.0012
ProFunds2026-01-31ULTRASMALL-CAP PROFUND SERVICE CLASSUAPSX1,2241,080.550.002
ProFunds2026-01-31ULTRASMALL-CAP PROFUND INVESTOR CLASSUAPIX1,2241,080.550.002
This is a preview of the latest data. Subscribe to access the full data.